NOTTINGHAM, England--(BUSINESS WIRE)--Scancell Holdings Plc (‘Scancell’ or the ‘Company’), (PLUS:SCLP), the developer of therapeutic cancer vaccines, today announces a strategic collaboration with ImmuneRegen BioSciences, Inc.® (‘ImmuneRegen’), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC BB:IRBS.OB). Under the agreement, Scancell and ImmuneRegen will work together to investigate the synergy between ImmuneRegen’s Homspera® and Scancell’s ImmunoBody® vaccine technologies.
